Advertisement

Topics

Companies Related to "Trial compares laparoscopic open surgeries pancreatic cancer" [Most Relevant Company Matches] RSS

23:05 EST 13th December 2017 | BioPortfolio

Here are the most relevant search results for "Trial compares laparoscopic open surgeries pancreatic cancer" found in our extensive corporate database of over 50,000 company records.

Showing "Trial compares laparoscopic open surgeries pancreatic cancer" Companies 1–25 of 3,300+

Extremely Relevant

World Pancreatic Cancer Coalition

The World Pancreatic Cancer Coalition is an international group of pancreatic cancer patient advocacy groups with a mission to drive transformational change for all those affected by the disease. Through global collaboration, the coalition raises awareness of pancreatic cancer by strengthening the efforts of participating member organizations. Each Novembe...


Pancreatic Cancer Action

About Pancreatic Cancer Action: 5 year survival rates for pancreatic cancer have not changed in over 40 years and it is our mission to change this by way of increased awareness of pancreatic cancer within the general population, the medical community and the Government. We are developing educational programmes for trainee General Practitioners and are working on creating free Online Interactive...

Relevant

Sky Foundation, Inc.

After being diagnosed with pancreatic cancer in 2007 and responding well to treatment, Kasselman established Sky Foundation to fund research for the Sky Foundation Pancreatic Cancer Research Fund at the Barbara Ann Karmanos Cancer Institute to develop a diagnostic tool for the early detection of pancreatic cancer.


Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is the only national organization creating hope in a comprehensive way through research, patient support, community outreach and advocacy for a cure. The organization raises money for direct private funding of research -- and advocates for more aggressive federal research funding of medical breakthroughs in prevention, diagnosis and treatment of pancreatic canc...

The Lustgarten Foundation

The Lustgarten Foundation, based in Bethpage, New York, is America's largest private foundation dedicated solely to funding pancreatic cancer research. Founded in 1998, the Foundation provides critical support in the search for better diagnostics and treatment of pancreatic cancer, and to date has provided more than $32 million to more than 115 research projects at 41 medical and research centers ...

Bandaid Surgery, PC

Laparoscopic colon surgery, also known as band-aid colon surgery, is a revolutionary colorectal surgical technique pioneered and perfected by Dr.David Blumberg, a Board Certified General and Colorectal Surgeon while in the Department of Surgery at the University of Pittsburgh Medical Center. Company Overview: Band-aid colon surgery is a revolutionary colorectal surgical technique pioneered...

Kenner Family Research Fund

Kenner Family Research Fund (KFRF) was formed by family and friends of Peter Kenner, who died shortly after his diagnosis of neuroendocrine pancreatic cancer. KFRF (a fund of JCF, a registered 501(c)3 organization) is committed to the development of an early detection protocol for pancreatic cancer that will be used by primary care physicians (www.kennerfa...

The Lustgarten Foundation for Pancreatic Cancer Research

Founded in 1998 by Cablevision executive Marc Lustgarten, with Cablevision chairman Charles Dolan and CEO James Dolan, The Lustgarten Foundation is the nation's largest private, non-profit supporter of pancreatic cancer research, providing more than $20 million to date. The Foundation provides patient information and manages a national public awareness campaign. To learn more and to see Dr. Pa...

Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines and therapeutic antibodies. The Company is focusing on development ...

GlycoGenesys, Inc.

GlycoGenesys, Inc. is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product, GCS-100, a unique compound to treat cancer has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. In February 2002, the Company initiated a Phase I dose escalation trial of GCS-100 up to 80 mg/m2 at Sharp Clin...

Suture Ease Inc.

Based in San Jose, California, Suture Ease develops and markets innovative technologies that combine efficacy and ease of use to enhance laparoscopic procedures. A fundamental element of laparoscopic surgery is port site access. Frequently procedures require one or more of these ports to be larger than 10mm, necessitating closure at the end of the procedur...

Health Consumer Powerhouse (HCP)

The Health Consumer Powerhouse (HCP) monitors and compares healthcare systems among 35 countries, including all EU member states as well as Canada. Open benchmarking improves performance. Presenting our conclusions through 50 various health consumer index editions, we provide guidance to patients and citizens, reality checks to governments and marketing opportunities to our sponsors. In 2005,...

Cancer Prevention Pharmaceuticals, Inc.

Cancer Prevention Pharmaceuticals, Inc. (CPP) is developing therapeutics designed to reduce the risk of cancer and other diseases. CPP’s pharmaco-prevention approach has been used with success in other disease categories such as cardiovascular, neurovascular, and infectious disease. In addition to the CPP FAP-310 trial, CPP is co-sponsoring with the N...

Acessa Health Inc.

The Acessa System is the only radiofrequency ablation system cleared by the U.S. Food and Drug Administration and CE marked for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance. It has been the subject of 20 peer-reviewed publications across...

Lumicell, Inc.

Lumicell is a leader in the field of image-guided cancer surgery. The company is developing a revolutionary intraoperative imaging system that gives surgeons real-time visual feedback of residual cancer in the tumor bed. Lumicell’s surgical system includes a margin-targeted injectable imaging agent and a novel hand-held imaging device with exquisite s...

Nezhat

Drs. Camran Nezhat, Farr Nezhat, and Ceana Nezhat are recognized as the international leaders in the field of minimally invasive surgery and have pioneered the development of many laparoscopic procedures in the disciplines of gynecology, urology, and general surgery.Their innovative techniques, such as videolaparoscopy (laparoscopic surgery performed with the aid of a videotransmission of the insi...

Microline Surgical, Inc.

Headquartered in Beverly, Massachusetts, Microline Surgical, Inc. is a leading U.S. medical device manufacturer of high quality reposable surgical laparoscopic instruments. Founded in 1987, Microline is a wholly owned subsidiary of HOYA Corporation (7741:TSE) in Tokyo, Japan, a $4.5 billion company with approximately half of its revenues from medical busin...

BioTechNews Denmark

TopoTarget and CuraGen Announce Initiation of NCI-sponsored Phase II Clinical Trial with PXD101 for MesotheliomaTopoTarget A/S and CuraGen Corporation announced today the initiation of patient dosing in a Phase II clinical trial evaluating the activity of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of mesothelioma. This trial is being sponsored by the National ...

Vicus Therapeutics, LLC

Vicus Therapeutics is a biopharmaceutical company dedicated to bringing breakthrough therapies to patients with cancer. Vicus' lead investigational therapy, VT-122, is a combination of etodolac and propranolol. VT-122 showed positive results in a Phase 2 clinical trial of lung cancer patients and is currently being evaluated in a Phase 2 clinical trial of liver cancer patients receiving Nexavar ...

eClinicalHealth Limited

Headquartered in Scotland, eClinicalHealth Limited, developers of the ClinpalTM remote research platform, was founded in 2012 to provide innovative clinical trial solutions. The company is committed to leading open and collaborative innovation discussions about patient-centric clinical trial processes and technology with pharmaceutical companies, CROs and ...

Callisto Pharmaceuticals, Inc.

Callisto Pharmaceuticals, Inc., is a publicly traded biotechnology company on the American Stock Exchange (AMEX:KAL) and Frankfurt Exchange (CA4). Callisto's primary focus is the clinical development of two drugs to treat cancer, L-Annamycin for relapsed leukemia and Atiprimod for relapsed multiple myeloma (MM) and bone resorption. L-Annamycin, a drug from the anthracycline family, earlier complet...

eClinicalHealth

Headquartered in Scotland, eClinicalHealth Limited, developers of the revolutionary Clinpal patient engagement platform, was founded in early 2012 to provide innovative clinical trial solutions. The company is committed to leading open and collaborative innovation discussions about remote clinical trial processes and technology with pharmaceutical compa...

Cambridge Endo

Cambridge Endo is a privately held medical device company that designs, develops and manufactures innovative articulating laparoscopic instruments. The Autonomy(TM) Lapro-Angle(TM) product line is an enabling technology for Single Port Access surgery. Autonomy articulating instruments are also used in many traditional laparoscopic procedures by general surgeons, bariatric surgeons, urologic s...

ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently completed a Phase I trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. The Company is planning to initiate a ...

ImmunoCellular Therapeutics

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently completed a Phase I trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. The Company is planning to initiate a ...


More From BioPortfolio on "Trial compares laparoscopic open surgeries pancreatic cancer"

Quick Search
Advertisement
 

Corporate Database Quicklinks